Scarica l'app Stockscreener
5.00
3.31%
0.16
Pre-mercato:
4.99
-0.010
-0.20%
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
Jane Street Group LLC Sells 4,380 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $10.00 by Analysts at Oppenheimer - Defense World
URGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Rosen Law Firm Urges UroGen Pharma Ltd. (NASDAQ: URGN) Stockholders With Large Losses to Contact the Firm for Information About Their Rights - Business Wire
UROGEN PHARMA LTD. (NASDAQ: URGN) INVESTOR ALERT: Investors - GlobeNewswire
Oppenheimer Lowers Price Target for UroGen Pharma (URGN) to $10.00 | URGN Stock News - GuruFocus
Oppenheimer Adjusts UroGen Pharma Price Target to $10 From $36, Maintains Outperform Rating - marketscreener.com
UroGen Pharma Ltd. (URGN) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 28, 2025 Deadline - ACCESS Newswire
UroGen Pharma (URGN) Target Price Adjusted by Oppenheimer | URGN Stock News - GuruFocus
Oppenheimer lowers UroGen Pharma stock price target to $10 - Investing.com India
ProShare Advisors LLC Makes New $137,000 Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Malaysian Reserve
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
UroGen Pharma Ltd. (URGN) Launches uTRACT Registry to Track JELMYTO Use in UTUC - Insider Monkey
UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire
URGN STOCK: Suffer Losses on UroGen Pharma Ltd.? BFA Law - GlobeNewswire
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Desi - GuruFocus
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer - Business Wire
UroGen presents promising bladder cancer study results - Investing.com Australia
UroGen presents promising bladder cancer study results By Investing.com - Investing.com Canada
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) | URGN Stock News - GuruFocus
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Lost Money on UroGen Pharma Ltd. (URGN)? Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - StreetInsider
Securities Lawsuit Alert: UroGen Pharma Ltd. (URGN) InvestorsContact Levi & Korsinsky Before July 28, 2025 - ACCESS Newswire
Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN)Join by July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. has been Sued - GlobeNewswire
Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Possible Securities Fraud - ACCESS Newswire
Pharma Co. Hid Cancer Study Method Problems, Investor Claims - Law360
URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - The Malaysian Reserve
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors - Business Wire
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd. - GlobeNewswire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against ... - Eagle-Tribune
Investigation Opened on Behalf of UroGen Pharma Ltd. (URGN) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN)Contact Levi & Korsinsky - ACCESS Newswire
Did UroGen Pharma Ltd. (URGN) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
URGN FRAUD ALERT: UroGen Pharma Ltd. Investors are Alerted to Contact BFA Law about the Pending Securities Fraud Class Action - Newsfile
URGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire
UroGen Investor Sues After Cancer Therapy Setback, 45% Selloff - Bloomberg Law News
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit - Morningstar
UroGen Pharma Ltd. Investors: Please contact the Portnoy - GlobeNewswire
URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - Business Wire
Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action - Business Wire
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor ScrutinyHagens Berman - PR Newswire
Lost Investment in UroGen Pharma Ltd. (URGN)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
Oppenheimer maintains Outperform on UroGen Pharma stock By Investing.com - Investing.com South Africa
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA - New Castle News
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s - GlobeNewswire
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Position Decreased by Millennium Management LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
0.87%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):